Gene Expression Profiling for Aggressive B-Cell Lymphoma Subtyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches for aggressive B-cell lymphomas, particularly those with MYC and BCL2 rearrangements, lack specificity and effectiveness, leading to poor outcomes for patients with high-grade B-cell lymphomas.
Innovation Solution
A gene expression profiling method using a panel of 104 genes (DHIT signature) to classify aggressive B-cell lymphomas into two molecular subgroups: DHITsig-pos and DHITsig-neg, enabling precise diagnosis, prognosis, and therapy selection by determining the expression levels of specific genes in test samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic and therapeutic approaches are used for aggressive B-cell lymphomas, then treatment can be provided to patients, but the approaches lack specificity and effectiveness leading to poor patient outcomes
Solution Approach 1:
The patent segments aggressive B-cell lymphomas into distinct molecular subgroups (GCB and ABC) based on gene expression profiles of specific markers (e.g., Lymph67, Lymph2Cx signatures). This segmentation allows for precise diagnostic classification and tailored therapeutic approaches for each subgroup, resolving the contradiction by improving both diagnostic specificity and treatment effectiveness through subgroup-specific strategies.
2Measurement precision
If gene expression profiling with 104 genes (DHIT signature) is used to classify lymphomas, then accurate classification and prognosis are achieved, but the complexity of the diagnostic method increases
Solution Approach 1:
The patent extracts and focuses on specific critical gene signatures (Lymph67, Lymph2Cx) from the broader 104-gene DHIT signature to achieve accurate classification. By taking out only the most relevant gene markers needed for distinguishing molecular subgroups, the method maintains high classification accuracy while reducing diagnostic complexity compared to analyzing all 104 genes.
Solution Approach 2:
The patent applies local quality by using different gene expression profiles for different classification purposes: Lymph67 for germinal center origin identification, Lymph2Cx for molecular subgroup classification, and DHIT signature for high-grade lymphoma identification. Each gene panel is optimized for its specific diagnostic function, achieving accurate classification without requiring all genes to be analyzed simultaneously.
3Adaptability or versatility
If molecular subgroups are identified through gene expression profiling, then tailored therapy selection is enabled, but additional testing time and resources are required
Solution Approach 1:
The patent performs preliminary molecular subgroup classification using gene expression profiling (Lymph67, Lymph2Cx) before final treatment decisions are made. This preliminary action identifies patients who may benefit from alternative therapies versus standard R-CHOP, allowing clinicians to prepare targeted treatment strategies in advance and avoid unnecessary delays in treatment initiation.
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
The present invention relates to gene expression profiles for B-cell lymphoma. More specifically, the present invention relates to gene expression profiles for diagnosis, prognosis or therapy selection for an aggressive B-cell lymphoma.